Sheridan, Wyo. – September 10, 2026 -- The global stem cells market is projected to expand from USD 18.9 billion in 2026 to USD 32.57 billion by 2031, growing at a compound annual rate of 11.5%, according to a new study by Wissen Research.
Manufacturing gains, not new discoveries, drive the current growth phase
Analysts say the market's momentum stems largely from improvements in how cells are harvested, cultured, isolated, expanded and cryogenically preserved, rather than from newly identified therapeutic uses. Induced pluripotent stem cells (iPSCs) are drawing particular attention because they can be generated from adult tissue, avoiding sourcing and ethical issues tied to embryonic cells. Allogeneic, donor-derived therapies are also gaining share because they allow bulk, off-the-shelf manufacturing instead of custom batches per patient.
Adult stem cells held 72% of 2025 revenue on established clinical use
Adult stem cells, particularly hematopoietic and mesenchymal types, led the product segment with roughly 72% of global revenue in 2025, reflecting decades of use in transplantation and tissue repair. Pharmaceutical and biotechnology companies represented the largest end-user group at around 55% of revenue, as these firms lean on stem cells for drug testing and therapeutic development. Allogeneic therapies captured approximately 60% share by therapy type, favored for scalability.
North America leads with 44% share; Asia-Pacific grows fastest
North America held close to 44% of the market in 2025, supported by a dense concentration of biotech companies, research institutions and mature clinical trial infrastructure. Asia-Pacific is expanding fastest, propelled by rising healthcare investment and biotech infrastructure buildout in China, Japan, South Korea and India.
Partnerships and capital raises signal consolidation of scaling routes
In March 2026, Applied StemCell and Cellipont Bioservices announced a collaboration to speed up development of iPSC-derived cell therapies, combining engineering and banking capabilities with manufacturing and regulatory support. In January 2026, Aspect Biosystems deepened its partnership with Novo Nordisk on stem cell-derived diabetes treatments, gaining access to Novo Nordisk's islet cell and hypoimmune cell engineering technology along with added funding. That same month, South Korea's MEDIPOST raised roughly USD 140 million to advance its donor-derived mesenchymal stem cell therapy through late-stage clinical trials and expand manufacturing capacity.
Regulatory complexity and workforce shortages remain key barriers
Manufacturing cell-based therapies involves tightly controlled processes, and maintaining consistent quality and safety at scale adds technical and financial complexity, the report notes. Regulatory pathways for cell-based therapies tend to be more demanding than for conventional drugs, while a shortage of skilled personnel capable of running advanced cell processing operations continues to slow capacity expansion for companies trying to scale.